GSK’s hepatitis B drug touts functional curative potential in double Phase III win
GSK and Ionis Pharmaceuticals’ genetic medicine, bepirovirsen, has demonstrated its functional curative potential in chronic hepatitis B (CHB)…
Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B
– Pivotal B-Well data show significant 19% functional cure rate in the overall study population and 26% in…